Lifecore Secures Seventh Late-Stage High-Viscosity Neurology Suspension Manufacturing Agreement
LFCR•Lifecore Biomedical has secured its seventh late-stage pipeline agreement in seven months, signing a contract to perform technical transfer and commercial manufacturing of a high-viscosity injectable suspension for neurological disorders. This opportunity highlights rising demand for U.S. CDMO services in complex pharmaceutical formulations.
1. Agreement Terms
Lifecore will perform technical transfer services and commercial manufacturing of a high-viscosity injectable suspension for neurological disorders under a new agreement with a global pharmaceutical company.
2. Pipeline Expansion
This marks Lifecore’s seventh late-stage program agreement in the past seven months, reflecting accelerated business development efforts and continued portfolio growth.
3. Strategic Implications
The contract underscores growing demand for specialized U.S. CDMO expertise in complex formulations, positioning Lifecore as a key partner for high-viscosity pharmaceutical product manufacturing.
